Clinicopathological characteristics of patients with operable Her2_low breast cancer treated with neoadjuvant chemotherapy

Características clínico-patológicas de pacientes con cáncer de mama operable HER2_low tratadas con quimioterapia neoadyuvante

Published 2024-12-05

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 11 No. 2 (2024): Julio - Diciembre
Section
Original articles
How to Cite
Clinicopathological characteristics of patients with operable Her2_low breast cancer treated with neoadjuvant chemotherapy.
Rev. colomb. hematol. oncol. [Internet]. 2024 Dec. 5 [cited 2024 Dec. 22];11(2):12-21. Disponible en: https://doi.org/10.51643/22562915.665
DOI

https://doi.org/10.51643/22562915.665
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Javier Mauricio Cuello-López
Fundación Colombiana de Cancerología-Clínica Vida, Medellín, Colombia
    https://orcid.org/0000-0001-9741-5322
    Ana María Fidalgo-Zapata
    Clínica de Occidente
      https://orcid.org/0000-0001-6607-0114
      Laura Daniela López-Agudelo
      Hospital Alma Máter de Antioquia, Medellín, Colombia
        https://orcid.org/0000-0001-5274-5299
        Néstor Eduardo Llinás-Quintero
        Fundación Colombiana de Cancerología-Clínica Vida, Medellín, Colombia
          https://orcid.org/0000-0001-5408-0606
          Show authors biography

          Javier Mauricio Cuello-López,

          Oncólogo clínico. Grupo de Oncología Clínica, Fundación Colombiana de Cancerología-Clínica Vida, Medellín, Colombia.

          Ana María Fidalgo-Zapata,

          Mastóloga. Mastología, Clínica de Occidente, Cali, Colombia.

          Laura Daniela López-Agudelo,

          Anestesióloga. Anestesiología, Hospital Alma Máter de Antioquia, Medellín, Colombia.

          Néstor Eduardo Llinás-Quintero,

          Oncólogo clínico.  Grupo de Oncología Clínica, Fundación Colombiana de Cancerología-Clínica Vida, Medellín, Colombia.

          Objectives: To evaluate the clinical pathological characteristics of patients with operable Her2_low breast cancer treated with neoadjuvant chemotherapy and to identify clinicopathological variables related to survival. Methods: Observational, retrospective study in patients with operable Her2-negative breast cancer (Her2_low and Her2_zero) treated with neoadjuvant chemotherapy at Clínica Vida (Medellín) between 2013-2016. Clinical and pathological characteristics, response rates are described, and disease-free survival and overall survival were estimated between the Her2_low and Her2_zero subgroups. Results: 185 Her2_negative operable breast cancer patients treated with neoadjuvant chemotherapy were included. 80 patients (43.2%) were Her2_low subtypes, of these, 72% were luminal/Her2_low subtypes. There were no significant differences between stage T, stage N, histological grade, hormone receptor status between the Her2_zero Vs Her2_low groups. The pathologic complete response rate was similar between the Her2_low Vs Her2_zero subgroups. With a median follow-up of 79.6 months, DFS and OS are similar between subgroups of the Her2-negative population. Her2_low patients without progesterone receptor expression and ypN+ disease were associated with higher mortality rates. Conclusions: Her2-negative breast cancer subtype Her2_low appears to have a similar clinical course to the Her2-negative (0) population treated with neoadjuvant chemotherapy. Residual ypN+ disease and progesterone receptor expression have prognostic value in Her2_low breast cancer treated with neoadjuvant chemotherapy.

          Article visits 24 | PDF visits 25

          1. Early Breast Cancer Trialists' Collaborative Group. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology [Internet]. 2018;19(1):27-39. Disponible en: https://doi.org/10.1016/S1470-2045(17)30777-5.
          2. Tinterri C, Fernandes B, Zambelli A, Sagona A, Barbieri E, Di Maria Grimaldi S, et al. The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy. Cancers (Basel) [Internet]. 2024;16(2). Disponible en: https://doi.org/10.3390/cancers16020376.
          3. Nicolo E, Tarantino P, Curigliano G. Biology and Treatment of HER2-Low Breast Cancer. Hematol Oncol Clin North Am [Internet]. 2023;37(1):117-32. Disponible en: https://doi.org/10.1016/j.hoc.2022.08.013.
          4. Tarantino P, Curigliano G, Tolaney SM. Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. Cancer Discov [Internet]. 2022;12(9):2026-30. Disponible en: https://doi.org/10.1158/2159-8290.CD-22-0703.
          5. Tarantino P, Gandini S, Nicolo E, Trillo P, Giugliano F, Zagami P, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer [Internet]. 2022;163:35-43. Disponible en: https://doi.org/10.1016/j.ejca.2021.12.022.
          6. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. Journal of clinical oncology: official journal of the American Society of Clinical Oncology [Internet]. 2020;38(17):1951-62. Disponible en: https://doi.org/10.1200/JCO.19.02488.
          7. Bartsch R. ESMO 2020: highlights in breast cancer. Memo [Internet]. 2021:1-4. Disponible en: https://doi.org/10.1007/s12254-021-00713-5.
          8. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw [Internet]. 2020;18(4):452-78. Disponible en: https://doi.org/10.6004/jnccn.2020.0016.
          9. Loi S. The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO [Internet]. 2019;30(8):1183-4. Disponible en: https://doi.org/10.1093/annonc/mdz201.
          10. Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med [Internet]. 2017;376(22):2147-59. Disponible en: https://doi.org/10.1056/NEJMoa1612645.
          11. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med [Internet]. 2019;380(7):617-28. Disponible en: https://doi.org/10.1056/NEJMoa1814017.
          12. Cortazar P, Geyer CE, Jr. Pathological complete response in neoadjuvant treatment of breast cancer. Annals of surgical oncology [Internet]. 2015;22(5):1441-6. Disponible en: https://doi.org/10.1245/s10434-015-4404-8.
          13. de Glas NA, Bastiaannet E, Engels CC, de Craen AJ, Putter H, van de Velde CJ, et al. Validity of the online PREDICT tool in older patients with breast cancer: a population-based study. British journal of cancer [Internet]. 2016;114(4):395-400. Disponible en: https://doi.org/10.1038/bjc.2015.466.
          14. Rinnerthaler G, Gampenrieder SP, Greil R. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. Int J Mol Sci [Internet]. 2019;20(5). Disponible en: https://doi.org/10.3390/ijms20051115.
          15. Tarantino P, Niman SM, Erick TK, Priedigkeit N, Harrison BT, Giordano A, et al. HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications. Eur J Cancer [Internet]. 2022;174:277-86. Disponible en: https://doi.org/10.1016/j.ejca.2022.07.001.
          16. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med [Internet]. 2022;387(1):9-20. Disponible en: https://doi.org/10.1056/NEJMoa2203690.
          17. Zhou S, Liu T, Kuang X, Zhen T, Shi H, Lin Y, et al. Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer. Breast [Internet]. 2022;67:1-7. Disponible en: https://doi.org/10.1016/j.breast.2022.12.006.
          18. de Moura Leite L, Cesca MG, Tavares MC, Santana DM, Saldanha EF, Guimaraes PT, et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast cancer research and treatment [Internet]. 2021;190(1):155-63. Disponible en: https://doi.org/10.1007/s10549-021-06365-7.
          19. Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. The Lancet Oncology [Internet]. 2021;22(8):1151-61. Disponible en: https://doi.org/10.1016/S1470-2045(21)00301-6.
          20. Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer [Internet]. 2021;7(1):1. Disponible en: https://doi.org/10.1038/s41523-020-00208-2.
          21. Rey-Vargas L, Bejarano-Rivera LM, Ballen DF, Serrano-Gomez SJ. Characterization of HER2-Low Breast Tumors among a Cohort of Colombian Women. Cancers (Basel) [Internet]. 2024;16(18). Disponible en: https://doi.org/10.3390/cancers16183141.
          22. Li Z, Wei H, Li S, Wu P, Mao X. The Role of Progesterone Receptors in Breast Cancer. Drug Des Devel Ther [Internet]. 2022;16:305-14. Disponible en: https://doi.org/10.2147/DDDT.S336643.
          23. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology [Internet]. 2005;23(30):7721-35. Disponible en: https://doi.org/10.1200/JCO.2005.09.004.
          24. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Journal of the National Cancer Institute [Internet]. 2005;97(17):1254-61. Disponible en: https://doi.org/10.1093/jnci/dji249.

          Information

          Directories and indexers
          Google Scholar profile

          QR code

          Keywords

          Most read in the last 30 days

          Current Issue

          Sistema OJS 3.4.0.7 - Metabiblioteca |